can retatrutide cause pancreatitis Risk: How Common Is It Really? Retatrutide & Pancreatic Cancer Research

Retatrutide's GIP component improves tolerability and insulin sensitivity

The TRIUMPH-4 Phase 3 trial showed 28.7% average weight loss with retatrutide 12 mg at 68 weeks, compared to 14.9% to 17.4% with semaglutide 2.4 mg across STEP trials

Book your weight loss consultation today and discover a smarter, medically supervised path to weight loss in Plantation, FL.

Our physician-led team is always available to you, offering expert support and science-based care whenever you need it

Glucose-dependent insulinotropic polypeptide (GIP), which reduces appetite and triggers the pancreas to release insulin

Many people regain some or all of the weight, and blood sugar levels often rise again in those with diabetes